Skip to main content

Alzheimer’s Disease

Alliance Convenes Experts in Alzheimer’s at 18th Annual FDA/ACT-AD Allies Meeting

Alliance Convenes Experts in Alzheimer’s at 18th Annual FDA/ACT-AD Allies Meeting

January 21, 2026

Report: Major Flaws in CMS Nursing Home Quality Measure Hindering Alzheimer’s Care

Report: Major Flaws in CMS Nursing Home Quality Measure Hindering Alzheimer’s Care

November 18, 2025

New Survey Reveals Critical Gaps in Awareness and Understanding of Agitation in Alzheimer’s Dementia

New Survey Reveals Critical Gaps in Awareness and Understanding of Agitation in Alzheimer’s Dementia

November 12, 2025

Expert Guidance for Navigating Burdensome, Lesser-Known Symptoms of Alzheimer’s Disease

Expert Guidance for Navigating Burdensome, Lesser-Known Symptoms of Alzheimer’s Disease

June 10, 2025

Organizations and Researchers to HHS: Reverse Federal Layoffs, Reduction in Force

Organizations and Researchers to HHS: Reverse Federal Layoffs, Reduction in Force

March 31, 2025

Three Reasons for Urging FDA Reanalysis of Boxed Warnings on Antipsychotics

Three Reasons for Urging FDA Reanalysis of Boxed Warnings on Antipsychotics

December 10, 2024

New Poll: Bipartisan Majority Believes Medicare Beneficiaries Should Have Access to FDA-approved Early Alzheimer’s Medications the Same Way They Do for All Other Diseases

New Poll: Bipartisan Majority Believes Medicare Beneficiaries Should Have Access to FDA-approved Early Alzheimer’s Medications the Same Way They Do for All Other Diseases

October 10, 2024

Pathways to Parity Program Approved for 0K PCORI Engagement Award

Pathways to Parity Program Approved for $250K PCORI Engagement Award

August 12, 2024

Alliance Celebrates Second-Ever FDA Traditional Approval of Disease-Modifying Therapy for Alzheimer’s and Calls on Medicare to Stop Rationing Coverage

Alliance Celebrates Second-Ever FDA Traditional Approval of Disease-Modifying Therapy for Alzheimer’s and Calls on Medicare to Stop Rationing Coverage

July 2, 2024

Alliance to FDA About Potential Donanemab Approval: ‘It’s Critical That We Get This Right’

Alliance to FDA About Potential Donanemab Approval: ‘It’s Critical That We Get This Right’

June 10, 2024

Alliance’s ACT-AD, Leading Organizations Share Feedback on Alzheimer’s Research

Alliance’s ACT-AD, Leading Organizations Share Feedback on Alzheimer’s Research

June 10, 2024

Alliance Comment on Advisory Council on Alzheimer’s Research, Care, and Services

Alliance Comment on Advisory Council on Alzheimer’s Research, Care, and Services

January 22, 2024

Project PAUSE Addresses Concerns Related to Long-Term Care Facility Staffing, Antipsychotic Medication Metrics

Project PAUSE Addresses Concerns Related to Long-Term Care Facility Staffing, Antipsychotic Medication Metrics

November 7, 2023

Alliance Public Comment: Stop Conflating Staffing Issues with Inappropriate Use of Antipsychotics

Alliance Public Comment: Stop Conflating Staffing Issues with Inappropriate Use of Antipsychotics

October 30, 2023

Alliance Applauds Medicare Decision to End Restrictions on Access to Alzheimer’s Diagnostics

Alliance Applauds Medicare Decision to End Restrictions on Access to Alzheimer’s Diagnostics

October 13, 2023

Alliance Offers Recommendations to Keep Patients at Center of Payment-Related Decision-Making

Alliance Offers Recommendations to Keep Patients at Center of Payment-Related Decision-Making

September 12, 2023